Reminder: The pictures displayed on this site maybe different from the actual appearance of the product,their maybe a delay in updating the recent picture if their a newly launched packaging from the manufacturer
HERNIX is an irreversible tyrosine kinase inhibitor that is taken orally. It is the world's only medicine approved for intense adjuvant therapy after trastuzumab (Herceptin) treatment for HER2-positive breast cancer to lower the chance of recurrence. The target demographic is patients with undevelop
Please negotiate the logistics method with customer service, customer service Whatsapp/Wechat
Please follow the doctor’s advice when taking medicines. The mall only guarantees the quality of the medicines and does not provide medical advice.
HERNIX is a kinase inhibitor that binds to the Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Human Epidermal Growth Factor Receptor 4 (HER4) irreversibly. HERNIX inhibits autophosphorylation of EGFR and HER2, as well as downstream MAPK and AKT signaling pathways, and has anticancer efficacy in EGFR and/or HER2 expressing carcinoma cell lines. HERNIX's human metabolites M3, M6, M7, and M11 inhibited the activity of EGFR, HER2, and HER4 in vitro. Oral neratinib therapy inhibited tumour growth in vivo in mice xenograft models employing tumour cell lines expressing HER2 and EGFR.
240 mg (6 pills) taken once a day with food for a year. Individual safety and tolerability dictates dosage pauses and/or dose reductions.